Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Royalty Pharma
RPRX
|
+$709M |
| 2 |
WIX.com
WIX
|
+$282M |
| 3 |
Spotify
SPOT
|
+$279M |
| 4 |
Mercado Libre
MELI
|
+$249M |
| 5 |
Roblox
RBLX
|
+$228M |
Top Sells
| 1 |
KE Holdings
BEKE
|
+$298M |
| 2 |
CBRE Group
CBRE
|
+$283M |
| 3 |
Tesla
TSLA
|
+$275M |
| 4 |
Amazon
AMZN
|
+$256M |
| 5 |
NVIDIA
NVDA
|
+$237M |
Sector Composition
| 1 | Consumer Discretionary | 27.47% |
| 2 | Healthcare | 25.5% |
| 3 | Technology | 17.5% |
| 4 | Communication Services | 10.66% |
| 5 | Financials | 6.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Alector
ALEC
$279M
| $3.6M | ﹤0.01% |
354,492
-37,859
| -10% | -$385K |
|
252
Globus Medical
GMED
$8.04B
| $3.6M | ﹤0.01% |
+64,077
| New | +$3.6M |
|
|
KC
253
Kingsoft Cloud Holdings
KC
$3.86B
| $3.53M | ﹤0.01% |
793,536
-2,565,996
| -76% | -$11.4M |
|
254
PACCAR
PCAR
$51.6B
| $3.51M | ﹤0.01% |
+64,002
| New | +$3.51M |
|
|
ZY
255
DELISTED
Zymergen Inc. Common Stock
ZY
| $3.47M | ﹤0.01% |
2,821,956
| – | – |
|
256
Charles River Laboratories
CRL
$7.97B
| $3.38M | ﹤0.01% |
+15,796
| New | +$3.38M |
|
|
SAGE
257
DELISTED
Sage Therapeutics
SAGE
| $2.86M | ﹤0.01% |
88,446
-10,320
| -10% | -$333K |
|
258
American Well
AMWL
$112M
| $2.73M | ﹤0.01% |
31,576
-3,402
| -10% | -$294K |
|
|
NCNA
259
NuCana
NCNA
$5.51M
| $2.65M | ﹤0.01% |
732
| – | – |
|
260
Adicet Bio
ACET
$63.5M
| $2.65M | ﹤0.01% |
181,626
| – | – |
|
|
CLLS
261
Cellectis
CLLS
$275M
| $2.49M | ﹤0.01% |
880,932
-201,163
| -19% | -$569K |
|
|
TRHC
262
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $2.13M | ﹤0.01% |
830,274
-1,416
| -0.2% | -$3.64K |
|
263
WEC Energy
WEC
$34.6B
| $1.91M | ﹤0.01% |
18,996
| – | – |
|
|
SBNY
264
DELISTED
Signature Bank
SBNY
| $1.79M | ﹤0.01% |
+10,002
| New | +$1.79M |
|
265
Fortis
FTS
$24.6B
| $1.6M | ﹤0.01% |
33,889
| – | – |
|
266
Golub Capital BDC
GBDC
$3.95B
| $1.58M | ﹤0.01% |
122,100
-2,856,135
| -96% | -$37M |
|
267
Sixth Street Specialty
TSLX
$2.33B
| $1.47M | ﹤0.01% |
79,500
-1,035,200
| -93% | -$19.2M |
|
268
Bilibili
BILI
$9.31B
| $1.43M | ﹤0.01% |
55,974
-109,972
| -66% | -$2.82M |
|
269
Newmont
NEM
$83.2B
| $1.36M | ﹤0.01% |
22,787
-785
| -3% | -$46.9K |
|
270
Exelon
EXC
$43.4B
| $1.29M | ﹤0.01% |
28,452
| – | – |
|
271
Ameren
AEE
$27B
| $1.17M | ﹤0.01% |
12,931
| – | – |
|
272
Transmedics
TMDX
$3.6B
| $1.06M | ﹤0.01% |
33,727
-1,452
| -4% | -$45.6K |
|
273
Spire Global
SPIR
$278M
| $1.01M | ﹤0.01% |
108,256
| – | – |
|
274
PagSeguro Digital
PAGS
$2.78B
| $987K | ﹤0.01% |
96,324
+96,176
| +64,984% | +$985K |
|
|
BNR
275
Burning Rock Biotech
BNR
$97.5M
| $983K | ﹤0.01% |
33,789
-857,336
| -96% | -$24.9M |
|